$TNGX
Tango Therapeutics, Inc. Stock $tngx

$tngx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024032516 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$6.471M	$5.431M	$36.53M
YoY Change	12.23%	-15.29%	46.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.66M	$9.105M	$35.50M
YoY Change	33.05%	15.44%	18.24%
% of Gross Profit
Research & Development	$38.07M	$31.34M	$115.2M
YoY Change	35.76%	7.73%	8.77%
% of Gross Profit
Depreciation & Amortization	$600.0K	$617.0K	$2.400M
YoY Change	0.0%	8.25%	50.0%
% of Gross Profit
Operating Expenses	$48.73M	$40.44M	$150.7M
YoY Change	35.15%	9.37%	10.87%
Operating Profit	-$42.26M		-$114.2M
YoY Change	39.52%		2.79%
Interest Expense	$2.197M	$2.236M	$6.619M
YoY Change	107.07%	278.34%	354.6%
% of Operating Profit
Other Income/Expense, Net	$4.381M	$2.061M	$12.56M
YoY Change	92.32%	113.13%	326.01%
Pretax Income	-$37.87M	-$30.72M	-$101.6M
YoY Change	35.23%	5.88%	-6.02%
Income Tax	$40.00K	$47.00K	$100.0K
% Of Pretax Income
Net Earnings	-$37.91M	-$30.76M	-$101.7M
YoY Change	35.37%	5.86%	-5.95%
Net Earnings / Revenue	-585.91%	-566.43%	-278.54%
Basic Earnings Per Share	-$0.35		-$1.08
Diluted Earnings Per Share	-$0.35	-$0.29	-$1.08
COMMON SHARES
Basic Shares Outstanding	106.7M		94.57M
Diluted Shares Outstanding	108.2M		94.57M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$343.6M	$336.9M	$336.9M
YoY Change	2.99%	-7.99%	-7.99%
Cash & Equivalents	$61.16M	$66.39M	$66.39M
Short-Term Investments	$282.4M	$270.5M	$270.5M
Other Short-Term Assets	$8.437M	$9.653M	$9.653M
YoY Change	-9.87%	35.22%	35.22%
Inventory
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$352.0M	$346.5M	$346.5M
YoY Change	2.63%	-7.66%	-7.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.522M	$9.908M	$53.42M
YoY Change	-14.26%	-8.97%	-7.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.00K	$46.00K	$2.613M
YoY Change	-42.11%	820.0%	-23.77%
Total Long-Term Assets	$54.19M	$56.03M	$56.03M
YoY Change	-10.84%	-8.45%	-8.45%
TOTAL ASSETS
Total Short-Term Assets	$352.0M	$346.5M	$346.5M
Total Long-Term Assets	$54.19M	$56.03M	$56.03M
Total Assets	$406.2M	$402.6M	$402.6M
YoY Change	0.61%	-7.77%	-7.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.898M	$2.785M	$2.785M
YoY Change	-38.09%	-37.46%	-37.46%
Accrued Expenses	$15.82M	$17.48M	$17.48M
YoY Change	18.69%	-9.25%	-9.25%
Deferred Revenue	$23.07M	$25.67M
YoY Change	-32.17%	-19.26%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$42.79M	$45.94M	$45.94M
YoY Change	-20.28%	-17.3%	-17.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$98.98M	$103.5M	$103.5M
YoY Change	-19.42%	-21.25%	-21.25%
Total Long-Term Liabilities	$98.98M	$103.5M	$103.5M
YoY Change	-19.42%	-21.25%	-21.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.79M	$45.94M	$45.94M
Total Long-Term Liabilities	$98.98M	$103.5M	$103.5M
Total Liabilities	$141.8M	$149.5M	$149.5M
YoY Change	-19.68%	-20.07%	-20.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$409.2M	-$371.3M
YoY Change	37.53%	37.75%
Common Stock	$107.0K	$102.0K
YoY Change	21.59%	15.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$264.5M	$253.1M	$253.1M
YoY Change
Total Liabilities & Shareholders Equity	$406.2M	$402.6M	$402.6M
YoY Change	0.61%	-7.77%	-7.77%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$37.91M	-$30.76M	-$101.7M
YoY Change	35.37%	5.86%	-5.95%
Depreciation, Depletion And Amortization	$600.0K	$617.0K	$2.400M
YoY Change	0.0%	8.25%	50.0%
Cash From Operating Activities	-$37.86M	-$27.47M	-$118.0M
YoY Change	8.45%	-2.83%	8.16%
INVESTING ACTIVITIES
Capital Expenditures	$195.0K	$226.0K	$1.526M
YoY Change	-68.55%	-78.29%	-80.16%
Acquisitions
YoY Change
Other Investing Activities	-$11.01M	$34.08M	$42.95M
YoY Change	-134.22%	-394.69%	25.99%
Cash From Investing Activities	-$11.20M	$33.85M	$41.43M
YoY Change	-135.51%	-368.56%	56.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	42.98M	1.467M	82.41M
YoY Change	58779.45%	178.37%	5002.54%
NET CHANGE
Cash From Operating Activities	-37.86M	-27.47M	-118.0M
Cash From Investing Activities	-11.20M	33.85M	41.43M
Cash From Financing Activities	42.98M	1.467M	82.41M
Net Change In Cash	-6.078M	7.852M	5.850M
YoY Change	85.14%	-119.46%	-107.22%
FREE CASH FLOW
Cash From Operating Activities	-$37.86M	-$27.47M	-$118.0M
Capital Expenditures	$195.0K	$226.0K	$1.526M
Free Cash Flow	-$38.05M	-$27.69M	-$119.5M
YoY Change	7.11%	-5.51%	2.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001819133
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	ecd	Trd Arr Duration TrdArrDuration	P215D
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://www.tangotx.com/20231231#MarketableDebtSecuritiesMember
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://www.tangotx.com/20231231#MarketableDebtSecuritiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://www.tangotx.com/20231231#MarketableDebtSecuritiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://www.tangotx.com/20231231#MarketableDebtSecuritiesMember
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#MarketableSecuritiesCurrent
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#MarketableSecuritiesCurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39485
CY2023	dei	Entity Registrant Name EntityRegistrantName	TANGO THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1195036
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 Brookline Ave
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 901
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02215
CY2023	dei	City Area Code CityAreaCode	857
CY2023	dei	Local Phone Number LocalPhoneNumber	320-4900
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	TNGX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	177400000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106718315
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25670000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	31792000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	35000
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	tngx	Trdarrexpirationdate Trdarrexpirationdate	11/1/2024
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66385000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59968000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	270500000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	306165000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2000000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	856000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	567000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8797000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6572000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	346538000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	375272000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9908000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10884000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43508000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46886000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2567000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3423000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000
CY2023Q4	us-gaap	Assets Assets	402567000
CY2022Q4	us-gaap	Assets Assets	436470000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2785000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4453000
CY2023Q4	tngx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	15401000
CY2022Q4	tngx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	17495000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2082000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1770000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45938000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55545000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36838000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39361000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	66683000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	92088000
CY2023Q4	us-gaap	Liabilities Liabilities	149459000
CY2022Q4	us-gaap	Liabilities Liabilities	186994000
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102202759
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102202759
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88179374
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88179374
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	102000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	88000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	624076000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	522605000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	186000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3705000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-371256000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-269512000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	253108000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	249476000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	402567000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	436470000
CY2023	us-gaap	Revenues Revenues	36527000
CY2022	us-gaap	Revenues Revenues	24860000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	115198000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105906000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35502000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30025000
CY2023	us-gaap	Operating Expenses OperatingExpenses	150700000
CY2022	us-gaap	Operating Expenses OperatingExpenses	135931000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-114173000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-111071000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6619000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1456000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5944000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1493000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12563000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2949000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101610000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108122000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	134000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	54000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-101744000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108176000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94572448
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94572448
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87820037
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87820037
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-101744000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108176000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3891000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2940000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97853000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111116000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	344747000
CY2022	tngx	Stock Issued During Period Value Stock Options And Employee Stock Purchase Plan Exercised StockIssuedDuringPeriodValueStockOptionsAndEmployeeStockPurchasePlanExercised	1623000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14230000
CY2022	tngx	Adjustments To Additional Paid In Capital Business Combination And Pipe Financing Issuance Costs AdjustmentsToAdditionalPaidInCapitalBusinessCombinationAndPipeFinancingIssuanceCosts	8000
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-2940000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108176000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	249476000
CY2023	tngx	Stock Issued During Period Value Stock Options And Employee Stock Purchase Plan Exercised StockIssuedDuringPeriodValueStockOptionsAndEmployeeStockPurchasePlanExercised	1941000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	19079000
CY2023	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	67722000
CY2023	tngx	Stock Issued During Period Value Pre Funded Warrants Issued StockIssuedDuringPeriodValuePreFundedWarrantsIssued	12054000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	689000
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	3891000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-101744000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	253108000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-101744000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108176000
CY2023	us-gaap	Depreciation Depreciation	2415000
CY2022	us-gaap	Depreciation Depreciation	1608000
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3606000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2420000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19079000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14230000
CY2023	tngx	Accretion On Marketable Securities1 AccretionOnMarketableSecurities1	-3394000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-22000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	669000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2000000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2225000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2056000
CY2022	tngx	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	-10125000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	41000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-122000
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1705000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1097000
CY2023	tngx	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-2029000
CY2022	tngx	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	7629000
CY2023	tngx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2439000
CY2022	tngx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	1700000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-31527000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16860000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117982000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-109080000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1526000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7692000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	353526000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	242595000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	310574000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	208504000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41426000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26399000
CY2023	tngx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet	80017000
CY2023	tngx	Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options And Purchase Of Shares Under Employee Stock Purchase Plans ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndPurchaseOfSharesUnderEmployeeStockPurchasePlans	1941000
CY2022	tngx	Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options And Purchase Of Shares Under Employee Stock Purchase Plans ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndPurchaseOfSharesUnderEmployeeStockPurchasePlans	1623000
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	689000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	241000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	8000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	82406000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1615000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5850000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-81066000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63958000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	145024000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	69808000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63958000
CY2023	tngx	Cash Paid For Leases CashPaidForLeases	5882000
CY2022	tngx	Cash Paid For Leases CashPaidForLeases	1413000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	38000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	131000
CY2022	tngx	Operating Lease Liabilities From Obtaining Right Of Use Assets OperatingLeaseLiabilitiesFromObtainingRightOfUseAssets	48352000
CY2023	tngx	Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification	-228000
CY2022	tngx	Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification	300000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company’s cash, cash equivalent and marketable securities balances are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company’s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2023 and 2022. At times, the Company’s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.</span>
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3400000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	4000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66385000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59968000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3423000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3990000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69808000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63958000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	tngx	Expected Dividend Assumed ExpectedDividendAssumed	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	270500000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309870000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3726000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3Y7M6D
CY2023Q4	tngx	Fair Value Asset Level1 To Level2 Transfer Amount FairValueAssetLevel1ToLevel2TransferAmount	0
CY2023Q4	tngx	Fair Value Asset Level2 To Level1 Transfer Amount FairValueAssetLevel2ToLevel1TransferAmount	0
CY2023Q4	tngx	Fair Value Liabilities Level1 To Level2 Transfer Amounts FairValueLiabilitiesLevel1ToLevel2TransferAmounts	0
CY2023Q4	tngx	Fair Value Liabilities Level2 To Level1 Transfer Amounts FairValueLiabilitiesLevel2ToLevel1TransferAmounts	0
CY2022Q4	tngx	Fair Value Asset Level1 To Level2 Transfer Amount FairValueAssetLevel1ToLevel2TransferAmount	0
CY2022Q4	tngx	Fair Value Asset Level2 To Level1 Transfer Amount FairValueAssetLevel2ToLevel1TransferAmount	0
CY2022Q4	tngx	Fair Value Liabilities Level1 To Level2 Transfer Amounts FairValueLiabilitiesLevel1ToLevel2TransferAmounts	0
CY2022Q4	tngx	Fair Value Liabilities Level2 To Level1 Transfer Amounts FairValueLiabilitiesLevel2ToLevel1TransferAmounts	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	270314000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	381000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	195000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	306165000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	59857000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	34000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	32164000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	161000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	92021000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	195000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	113132000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1267000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	122997000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2459000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	236129000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3726000
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1800000
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	500000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15897000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14565000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5989000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3681000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9908000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10884000
CY2023	us-gaap	Depreciation Depreciation	2400000
CY2022	us-gaap	Depreciation Depreciation	1600000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7910000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5738000
CY2023Q4	tngx	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	6204000
CY2022Q4	tngx	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	10490000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1287000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1267000
CY2023Q4	tngx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	15401000
CY2022Q4	tngx	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	17495000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43500000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46900000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	5526000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4079000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	3815000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	476000
CY2023	us-gaap	Sublease Income SubleaseIncome	1467000
CY2022	us-gaap	Sublease Income SubleaseIncome	101000
CY2023	us-gaap	Lease Cost LeaseCost	7874000
CY2022	us-gaap	Lease Cost LeaseCost	4454000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	5188000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	82000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5101000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5608000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5776000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5949000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6128000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	26982000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	55544000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16624000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	38920000
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holder of each share of common stock is entitled to one vote in respect of each share of stock held.
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102202759
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102202759
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88179374
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88179374
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12924086
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.50
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M17D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24267448000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5427552
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.41
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	498973
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.22
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1117705
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.48
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16734960
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.21
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M29D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62640906000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7878781
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M19D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	32213577000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.041
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19079000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14230000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.067
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058
CY2023	tngx	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.063
CY2022	tngx	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.035
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.015
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.318
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.291
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16579000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7601000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18798000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10893000
CY2023Q4	tngx	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	12621000
CY2022Q4	tngx	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	13454000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	24644000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	31628000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1904000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1498000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	48257000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	28173000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4561000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2830000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	127364000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	96077000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	113397000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	81044000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13967000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15033000
CY2023Q4	tngx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	2126000
CY2022Q4	tngx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	2310000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	11841000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	12723000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13967000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15033000
CY2023Q4	tngx	Percentage Of Increase In Ownership Percentage Over A Three Year Period PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod	0.50
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	32400000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	The Company maintains a 401(k) retirement savings plan for employees who satisfy certain eligibility requirements. The savings plan is intended to qualify for favorable tax treatment under Section 401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law.
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-101744000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-108176000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94572448
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94572448
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87820037
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87820037
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17492474
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12924086

Files In Submission

Name	View Source	Status
0000950170-24-032516-index-headers.html	Edgar Link	pending
0000950170-24-032516-index.html	Edgar Link	pending
0000950170-24-032516.txt	Edgar Link	pending
0000950170-24-032516-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img160062560_0.jpg	Edgar Link	pending
img160062560_1.jpg	Edgar Link	pending
img160062560_10.jpg	Edgar Link	pending
img160062560_11.jpg	Edgar Link	pending
img160062560_12.jpg	Edgar Link	pending
img160062560_13.jpg	Edgar Link	pending
img160062560_14.jpg	Edgar Link	pending
img160062560_15.jpg	Edgar Link	pending
img160062560_16.jpg	Edgar Link	pending
img160062560_17.jpg	Edgar Link	pending
img160062560_18.jpg	Edgar Link	pending
img160062560_19.jpg	Edgar Link	pending
img160062560_2.jpg	Edgar Link	pending
img160062560_20.jpg	Edgar Link	pending
img160062560_21.jpg	Edgar Link	pending
img160062560_3.jpg	Edgar Link	pending
img160062560_4.jpg	Edgar Link	pending
img160062560_5.jpg	Edgar Link	pending
img160062560_6.jpg	Edgar Link	pending
img160062560_7.jpg	Edgar Link	pending
img160062560_8.jpg	Edgar Link	pending
img160062560_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tngx-20231231.htm	Edgar Link	pending
tngx-20231231.xsd	Edgar Link	pending
tngx-ex21_1.htm	Edgar Link	pending
tngx-ex23_1.htm	Edgar Link	pending
tngx-ex31_1.htm	Edgar Link	pending
tngx-ex31_2.htm	Edgar Link	pending
tngx-ex32_1.htm	Edgar Link	pending
tngx-ex32_2.htm	Edgar Link	pending
tngx-ex97_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
tngx-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNGX
Tango Therapeutics, Inc. Stock $tngx

2024 Q1 Form 10-K Financial Statement

#000095017024032516 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNGX Tango Therapeutics, Inc. Stock $tngx

2024 Q1 Form 10-K Financial Statement

#000095017024032516 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNGX
Tango Therapeutics, Inc. Stock $tngx